SEMAGLUTIDE

If you are interested in either one of our weight loss injection programs and would like more information or would like to set up an appointment, give us a call or send us a message here. 

***LET US KNOW YOU SAW THIS ON OUR WEBSITE AND GET YOUR FIRST MONTH OF SEMAGLUTIDE FOR $250 OR YOUR FIRST MONTH OF TIRZEPATIDE FOR $300! (Does not include consultation fee or labs)

Tirzepatide is an injectable prescription medicine that was approved for diabetes by the Food and Drug Administration (FDA) in 2022 under the name Mounjaro for the treatment of Type II diabetes. As the first and only FDA-approved GIP and GLP-1 receptor agonist, Mounjaro is a single molecule that activates the body's receptors for GIP and GLP-1, which are natural incretin hormones.

In 2023, the U.S. Food and Drug Administration approved Zepbound (tirzepatide) injection for chronic weight management in adults with obesity (body mass index of 30 kilograms per square meter (kg/ m2) or greater) or overweight (body mass index of 27 kg/m2 or greater) with at least one weight-related condition (such as high blood pressure, type 2 diabetes or high cholesterol) for use, in addition to a reduced calorie diet and increased physical activity. 

Here at Beauty & Grace, we have the compounded version of tirzepatide. Tirzepatide activates receptors of hormones secreted from the intestine (glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP)) to reduce appetite and food intake. Tirzepatide is administered by injection under the skin once weekly, and the dosage must be increased over four to 20 weeks to achieve the target dosages of 5 milligram (mg), 10 mg or 15 mg once weekly. The maximum dosage of Tirzepatide is 15 mg once weekly.

Tirzepatide can cause side effects such as nausea, diarrhea, vomiting, constipation, abdominal (stomach) discomfort and pain, injection site reactions, fatigue, hypersensitivity (allergic) reactions (typically fever and rash), burping, hair loss and gastroesophageal reflux disease.

Semaglutide is a medication that has been approved for the treatment of type 2 diabetes, but it is also showing promise as a treatment for weight loss. Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist, which works by mimicking the actions of the hormone GLP-1 in the body. 

GLP-1 helps to regulate blood sugar levels by stimulating insulin secretion and suppressing glucagon secretion, which helps to reduce glucose production in the liver. In addition, GLP-1 has been shown to have appetite-suppressing effects, which can lead to weight loss.

Studies have shown that semaglutide can lead to significant weight loss in patients with obesity. In a clinical trial called STEP 1, patients who took semaglutide once a week lost an average of 15% of their body weight over 68 weeks, compared to 2.4% in the placebo group. 

In another trial called STEP 2, patients who took semaglutide once a week lost an average of 17.4% of their body weight over 68 weeks, compared to 5.7% in the placebo group.

Semaglutide treatment is thought to work by reducing food intake and increasing feelings of fullness. It is also believed to slow down the emptying of the stomach, which can help to reduce appetite. 

Semaglutide is administered by injection once a week, and it is generally well-tolerated by patients. The most common side effects include nausea, vomiting, and diarrhea, which typically resolve over time.

While semaglutide is not yet approved for the treatment of obesity, its promising results in clinical trials have led to increased interest in its potential use as a weight loss medication. 

Ongoing research is exploring the optimal dosing and duration of treatment, as well as the potential long-term effects of semaglutide on weight loss and overall health.

TIRZEPATIDE

Benefits of Semaglutide:

1. Helps decrease appetite.​

2. Helps regulate blood sugar.

3. Decreases insulin resistance.

4. Promotes weight loss.

5. Long term reduction in cardiovascular risk.